Celsion announces presentation of long-term follow-up data from Phase I ThermoDox dose escalation trial

Celsion Corporation (Nasdaq: CLSN) today announced that Dr. Ronnie T.P. Poon, a principal investigator of the Phase I ThermoDox® dose escalation trial, held a press conference at the University of Hong Kong to provide an update on the long-term follow-up data from patients treated at his center as well as present illustrative patient case studies.  The Phase I trial was conducted in 2006.  A presentation of the press conference is available on Celsion's website at www.celsion.com/events.cfm.

In addition to Dr. Poon's discussion, he addressed questions from an audience of nearly 30 television, radio, and newspaper media, in both Chinese and English.  "Our patients at the University of Hong Kong tolerated the treatment very well, and more importantly, three patients survived for more than three years after ThermoDox treatment, including one who is still in remission," said Dr. Ronnie T.P. Poon.

"The fact that some of these patients were refractory and had prior treatment makes these results even more impressive," remarked Michael H. Tardugno, President & Chief Executive Officer of Celsion Corporation.  "The addressable population could be even larger than we imagined before, considering the patient in remission had earlier treatments that were unsuccessful. Additionally, Professor Poon's report that of the 28 treated tumors, 87.5% demonstrated a complete ablation rate at 28 days, suggests improvement in RFA's efficacy to successfully treat local lesions."

SOURCE Celsion Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.